TCRR - Adaptimmune: TCR2 Merger Represents Opportunity For Enthusiastic Investors
2023-03-26 07:12:58 ET
Summary
- ADAP is down after merging with TCRR, while TCRR is up.
- The merger dilutes ADAP, but in return, it gets one year of additional cash and the TCRR pipeline for free.
- The merger looks like a smart deal for ADAP.
For further details see:
Adaptimmune: TCR2 Merger Represents Opportunity For Enthusiastic Investors